Telix Pharmaceuticals (TLX) Enterprise Value (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Enterprise Value data on file, last reported at -$141.9 million in Q4 2025.

• Enterprise Value for Q4 2025 came in at -$141.9 million, up 69.46% year-over-year; the trailing twelve-month figure through Dec 2025 was -$141.9 million (up 69.46% YoY), and the FY2025 annual result was -$141.9 million, up 69.46% from the prior year.
• Enterprise Value improved to -$141.9 million in Q4 2025 per TLX's latest filing, from -$464.5 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$80.2 million in Q4 2023 and troughed at -$464.5 million in Q4 2024.
• A 3-year average of -$228.9 million and a median of -$141.9 million in 2025 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value plunged 479.03% in 2024, then soared 69.46% in 2025.
• A 3-year view of Enterprise Value shows it stood at -$80.2 million in 2023, then sank by 479.03% to -$464.5 million in 2024, then soared by 69.46% to -$141.9 million in 2025.
• Business Quant data shows TLX's Enterprise Value at -$141.9 million in Q4 2025, -$464.5 million in Q4 2024, and -$80.2 million in Q4 2023.